Thursday Edition
Saturday Edition
Teriflunomide
Dimethyl fumarate
Fingolimod
Cladribine
Alemtuzumab
Ocrelizumab
Neurology
ECTRIMS 2017 DAILY REPORT – THURSDAY EDITION
October 26, 2017Cladribine: intermittent immunosuppression in MS
September 21, 2017SPECIAL REPORT
The next disease-modifying therapy (DMT) expected to become available in Canada is cladribine, an oral agent initially developed a decade ago (see The return of cladribine in RRMS, NeuroSens, August 23, 2017). The drug was approved by the European Medicines Agency in June, and is currently in review with Health Canada.
New findings on gut microbiome and MS
September 13, 2017A number of recent studies have suggested that alterations in the gut microbiome (dysbiosis) may contribute to the onset and/or worsening of multiple sclerosis. Two new papers, scheduled for publication this week, report that certain bacterial strains promote neurodegeneration in the EAE mouse model (Cekanaviciute and colleagues. PNAS 2017; in press). Read More
Seizure count an inaccurate endpoint in epilepsy trials
August 31, 2017Several recent studies have reported that patient-reported seizure count, a common endpoint used in clinical trials of antiepileptic agents, is highly inaccurate, with patients failing to report a majority of the seizures that occur. Read More